The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

Dr. Albritton is a resident physician and Dr. Kingdom is Assistant Professor in the Department of Otolaryngology at Emory University School of Medicine, Atlanta, Ga. Albritton FD, Kingdom TT.

The absorption of neffy may be affected in patients with underlying structural or anatomical nasal conditions (eg, nasal polyps, history of nasal surgery). In these patients, epinephrine products ...

Spicy foods are a common trigger for a runny nose while eating. This is due to a chilli pepper extract called capsaicin, ...

During a nasal endoscopy, the health care provider tries to look inside your nose or the opening of the sinus passage to ...

SNY's reasonable valuation, rising estimates, improving top line and positive pipeline progress are good enough reasons to ...

The fall flurry of biotech IPOs shows no signs of abating, with Upstream Bio becoming the latest company to express an ...

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca’s Fasenra (benralizumab) ...

Labelling warns that certain nasal conditions, such as nasal polyps or a history of nasal surgery, may affect the absorption of the new drug. ARS said it will launch the product onto the market ...

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...